Table 5.
95% Confidence Interval | ||||
---|---|---|---|---|
Predictor | Hazard Ratio | Lower | Upper | p-value |
Age (per year) | 1.02 | 1.00 | 1.05 | 0.02 |
Sex (female) | 0.79 | 0.52 | 1.20 | 0.27 |
Race (reference: White) | ||||
Black | 3.17 | 0.93 | 10.8 | 0.07 |
Other | 0.84 | 0.20 | 3.53 | 0.81 |
Year of diagnosis (per year) | 0.98 | 0.92 | 1.05 | 0.60 |
CDCC score (reference: 0) | ||||
1 | 1.09 | 0.78 | 1.52 | 0.63 |
2+ | 1.07 | 0.63 | 1.82 | 0.81 |
Insurance status (reference: government) | ||||
Private | 0.67 | 0.45 | 1.01 | 0.06 |
None | 1.60 | 0.37 | 6.89 | 0.53 |
Facility type (reference: non-academic) | ||||
Academic/Research Program | 0.91 | 0.67 | 1.24 | 0.54 |
Pathologic T stage (reference: T2) | ||||
T3 or T4a | 1.56 | 1.11 | 2.21 | 0.01 |
Tumor size (per mm) | 1.00 | 0.99 | 1.01 | 0.90 |
Grade (reference: moderately differentiated) | ||||
Well differentiated | 0.46 | 0.26 | 0.82 | 0.009 |
Adjuvant radiation (reference: none) | 0.89 | 0.29 | 2.71 | 0.84 |
Type of adjuvant therapy (reference: none) | ||||
Chemotherapy with or without radiation | 1.03 | 0.36 | 2.92 | 0.95 |
CDCC indicates Charlson-Deyo Comorbidity Index